Table 1

Clinical and sleep characteristics of multiple system atrophy (MSA) patients
Variables MSA patients
Patients 25
Male:Female 10:15
Age at onset (years) 62.3 ± 1.7 (46–78)
Disease duration (months) 45.9 ± 4.7 (12–96)
UMSARS 48.0 ± 4.0 (17–82)
ESS 6.2 ± 0.9 (0–15)
Total sleep time (min) 322 ± 18 (103–575)
Sleep efficiency (%) 61.9 ± 2.7 (35–95)
Stage N1 (%) 32.1 ± 2.26 (12.6–57.3)
Stage N2 (%) 46.3 ± 3.1 (11.4–69.8)
Stage N3 (%) 5.2 ± 1.4 (0–21.7)
Stage REM (%) 15.6 ± 2.5 (0–44.9)
Arousal index (/h) 43.0 ± 4.1 (0–79.9)
AI (/h) 19.7 ± 4.7 (0–80.8)
AHI (/h) 41.9 ± 6.4 (4.1–117.3)
Mean SpO2 (%) 93.1 ± 3.2 (82–97)
PLM index (/h) 44.2 ± 11.7 (0–166.0)
PLM arousal index (/h) 2.3 ± 0.9 (0–16.2)
LED (mg/day) 352 ± 50 (25–683)

Values are means ± standard error of the means (SEM; range). MSA, multiple system atrophy; UMSARS, unified multiple system atrophy rating scale; ESS, Epworth sleepiness scale; REM, rapid eye movement; AI, apnea index; AHI, apnea-hypopnea index; SpO2, oxygen saturation; PLM, periodic leg movement; LED, L-dopa-equivalent dose.

Shimohata et al.

Shimohata et al. BMC Neurology 2012 12:130   doi:10.1186/1471-2377-12-130

Open Data